IMGO NASDAQ
Imago BioSciences, Inc.
1W: +0.1%
1M: +0.4%
3M: +131.3%
1Y: +81.7%
$36.01
Last traded 2023-01-10 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range11.56-36.09
Volume138,127
Avg Volume762,778
Beta0.00
Dividend—
Analyst Ratings
Company Info
CEOHugh Young Rienhoff Jr.,
Employees41
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-16
Websitemerck.com
329 Oyster Point Boulevard
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
415 529 5055
About Imago BioSciences, Inc.
Imago BioSciences, Inc. is a clinical-stage biopharmaceutical firm specializing in the identification and advancement of small molecule product candidates. These candidates are designed to inhibit lysine-specific demethylase 1 (LSD1), an enzyme integral to the generation of blood cells within the bone marrow. The company's flagship therapeutic, bomedemstat, is presently undergoing Phase II clinical trials. It is being developed as a potential treatment for myeloproliferative neoplasms, a class of chronic bone marrow malignancies that includes conditions such as myelofibrosis, essential thrombocythemia, and polycythemia vera. Established in 2012, Imago BioSciences is headquartered in South San Francisco, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| KEATING LAURIE | D-Return | 11,904 | — | 2023-01-11 |
| Kariuki Enoch | D-Return | 11,904 | — | 2023-01-11 |
| Tapper Amy E. | U-Tender | 141,094 | $36.00 | 2023-01-11 |
| Tapper Amy E. | D-Return | 103,000 | — | 2023-01-11 |
| Rienhoff Hugh JR | U-Tender | 501,702 | $36.00 | 2023-01-11 |